- Home
- WEC vs ARGX Comparison
WEC vs ARGX Comparison
Compare WEC & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WEC
- ARGX
- Stock Information
- Founded
- WEC 1896
- ARGX 2008
- Country
- WEC United States
- ARGX Netherlands
- Employees
- WEC N/A
- ARGX N/A
- Industry
- WEC Power Generation
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WEC Utilities
- ARGX Health Care
- Exchange
- WEC Nasdaq
- ARGX Nasdaq
- Market Cap
- WEC 34.3B
- ARGX 40.4B
- IPO Year
- WEC N/A
- ARGX 2017
- Fundamental
- Price
- WEC $108.39
- ARGX $596.20
- Analyst Decision
- WEC Hold
- ARGX Strong Buy
- Analyst Count
- WEC 9
- ARGX 20
- Target Price
- WEC $101.11
- ARGX $699.56
- AVG Volume (30 Days)
- WEC 2.5M
- ARGX 465.0K
- Earning Date
- WEC 04-30-2025
- ARGX 05-08-2025
- Dividend Yield
- WEC 3.29%
- ARGX N/A
- EPS Growth
- WEC 14.45
- ARGX N/A
- EPS
- WEC 4.83
- ARGX 12.78
- Revenue
- WEC $8,599,900,000.00
- ARGX $2,248,205,000.00
- Revenue This Year
- WEC $9.76
- ARGX $57.86
- Revenue Next Year
- WEC $5.04
- ARGX $31.90
- P/E Ratio
- WEC $22.44
- ARGX $43.64
- Revenue Growth
- WEC N/A
- ARGX 77.22
- 52 Week Low
- WEC $77.47
- ARGX $352.77
- 52 Week High
- WEC $111.00
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- WEC 57.33
- ARGX 51.80
- Support Level
- WEC $107.07
- ARGX $583.00
- Resistance Level
- WEC $111.00
- ARGX $610.06
- Average True Range (ATR)
- WEC 2.91
- ARGX 24.42
- MACD
- WEC 0.13
- ARGX 4.74
- Stochastic Oscillator
- WEC 74.81
- ARGX 84.66
About WEC WEC Energy Group Inc.
WEC Energy Group's electric and gas utility businesses serve electric and gas customers in Illinois, Michigan, Minnesota, and Wisconsin service territories. The company also owns a 60% stake in American Transmission Co. WEC's asset mix is approximately 49% electric generation and distribution, 34% gas distribution, 10% electric transmission, and 7% unregulated renewable energy.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.